Hyperkalaemia is defined as abnormally elevated levels of potassium in the blood, a serious condition in cardio-renal patients that can be responsible for cardiac arrhythmias leading to cardiac arrest and death, with a resulting mortality rate of up to 30%.
Driving Value for Nephrology Patients
People living with Chronic Kidney Disease (CKD) face a long and difficult journey associated with multiple and varying conditions and complications that severely impact quality of life and life expectancy. We partner with specialists to improve the lives of patients with high unmet medical need and, through our innovative portfolio and individualized solutions, we aim to address the full spectrum of kidney disease across all stages of kidney failure, from early stages to late stages and dialysis settings.
CSL Vifor and the joint company created with Fresenius Medical Care, has combined CSL Vifor’s expertise in pharmaceuticals with the skills and infrastructure of Fresenius Medical Care. The Company treats around 340,000 patients in its global network of over 4,000 dialysis clinics and is the world’s leading provider of products and services for people with chronic kidney failure.
Below you can find the full list of the conditions we currently address.
Our Nephrology Products
Through our innovative portfolio, we aim to improve the lives of CKD patients through a broad range of therapies focused on distinct comorbidities and complications across all stages of CKD. Our continued success is underpinned by a diversified portfolio of commercial products and a promising pipeline.
Patients are at the center of everything we do and we are committed to identifying and supporting under-served therapeutic areas. By working closely with patients and integrating their voice across key areas of our business , we can develop solutions that benefit them in the best possible way and improve standards of care.See Our Patient Stories